- Home
- SGLY vs ENVB Comparison
SGLY vs ENVB Comparison
Compare SGLY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | ENVB |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.1M |
| IPO Year | 2008 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SGLY | ENVB |
|---|---|---|
| Price | $2.05 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 125.0K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,813,193.00 | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.56 |
| 52 Week High | $8.65 | $13.25 |
Technical Indicators
Market Signals| Indicator | SGLY | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 42.10 |
| Support Level | $0.38 | N/A |
| Resistance Level | $8.65 | $1.54 |
| Average True Range (ATR) | 1.14 | 0.12 |
| MACD | -0.56 | -0.01 |
| Stochastic Oscillator | 1.87 | 39.99 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.